Company news

Zymeworks Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals

November 28, 2022

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)

November 20, 2022

Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 7, 2022

Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms

October 19, 2022

Zymeworks Completes Plan to Become Delaware Corporation

October 12, 2022

Zymeworks Announces Results of Special Meeting

October 6, 2022

Zymeworks Reminds Shareholders to Vote FOR its Redomicile

October 3, 2022

Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress

September 11, 2022

Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware

September 7, 2022

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

September 3, 2022

Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 3, 2022

Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris

July 24, 2022

Zymeworks Reports Inducement Grant to New Chief Scientific Officer

July 21, 2022

Zymeworks Announces Plan to Become a Delaware Corporation

July 14, 2022

Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer

June 26, 2022

Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company

June 9, 2022

Zymeworks Announces Participation in Upcoming Investor Conference

May 26, 2022

Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal

May 19, 2022

Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 3, 2022

Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer

April 27, 2022

Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

April 26, 2022

Zymeworks to Host First Quarter 2022 Results Conference Call

April 18, 2022

Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results

February 23, 2022

Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call

February 7, 2022

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

January 30, 2022

Zymeworks Announces Pricing of $100.0 Million Public Offering

January 25, 2022

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022

January 18, 2022

Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule

January 14, 2022

Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani

January 4, 2022

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment

December 8, 2021

Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms

November 30, 2021

Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)

November 18, 2021

Zymeworks Names Neil Josephson, M.D., Chief Medical Officer

November 8, 2021

Zymeworks Reports 2021 Third Quarter Financial Results

November 2, 2021

Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers

October 25, 2021

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors

October 4, 2021

Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

September 11, 2021

Zymeworks Reports 2021 Second Quarter Financial Results

August 3, 2021

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms

August 2, 2021

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

July 27, 2021

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

May 5, 2021

Zymeworks Reports 2021 First Quarter Financial Results

May 4, 2021

Zymeworks Announces Succession Plan for Chief Medical Officer

April 18, 2021

Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

March 9, 2021

Zymeworks Reports 2020 Year-End Financial Results

February 23, 2021

Zymeworks Expands Commercial Team and Creates New R&D Role

February 8, 2021

Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development

January 26, 2021

Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

January 14, 2021

Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities

January 10, 2021

Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene

November 30, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.